These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 7384189)

  • 21. Statistical method for evaluation of dissolution stability in the formulation development of solid dosage forms: tablets of amonafide.
    Gil-Alegre ME; Bernabeu JA; Camacho MA; Torres-Suarez AI
    Pharmazie; 2004 Jul; 59(7):541-7. PubMed ID: 15296092
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Development of an oral rutin nanocrystal formulation.
    Mauludin R; Müller RH; Keck CM
    Int J Pharm; 2009 Mar; 370(1-2):202-9. PubMed ID: 19114097
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Preparation and, in vitro, preclinical and clinical studies of aceclofenac spherical agglomerates.
    Usha AN; Mutalik S; Reddy MS; Ranjith AK; Kushtagi P; Udupa N
    Eur J Pharm Biopharm; 2008 Oct; 70(2):674-83. PubMed ID: 18606224
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparative dissolution rate studies of commercial furosemide tablets.
    Gadalla MA; Ismail AA
    Pharmazie; 1981 Aug; 36(8):553-6. PubMed ID: 7291288
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [The dynamics of the drug release from tablets. Part 6: Liberation of glaucine from Tussiglauzin Dragées (author's transl)].
    Pasich J; Niedworok E; Warzecha U
    Pharmazie; 1980 Dec; 35(12):777. PubMed ID: 7208580
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Dissolution determination in the rotating flask model. Effect of rotation rate and fluid volume on the solubility determination of standard test tablets in the Resotest dissolution tester].
    Koch HP; Pfeifer G
    Pharmazie; 1983 May; 38(5):318-23. PubMed ID: 6611628
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Formulation, release characteristics and bioavailability of novel monolithic hydroxypropylmethylcellulose matrix tablets containing acetaminophen.
    Cao QR; Choi YW; Cui JH; Lee BJ
    J Control Release; 2005 Nov; 108(2-3):351-61. PubMed ID: 16154656
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Lot-to-lot variation in dissolution of tolbutamide tablets.
    Ayres JW
    Am J Hosp Pharm; 1980 Oct; 37(10):1329-32. PubMed ID: 7424928
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparison of two dissolution apparatuses: rotating basket versus rotating flask.
    Koch HP; Alcorn G; Ritschel WA
    Pharmazie; 1983 Apr; 38(4):233-5. PubMed ID: 6867085
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Influence of processing parameters and formulation factors on the drug release from tablets powder-coated with Eudragit L 100-55.
    Sauer D; Zheng W; Coots LB; McGinity JW
    Eur J Pharm Biopharm; 2007 Sep; 67(2):464-75. PubMed ID: 17451929
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Development of spray-dried co-precipitate of amorphous celecoxib containing storage and compression stabilizers.
    Dhumal RS; Shimpi SL; Paradkar AR
    Acta Pharm; 2007 Sep; 57(3):287-300. PubMed ID: 17878109
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [The polymorphism of drugs in powders and tablets. 1. The preparation and characterization of polymorphic modifications of phenobarbital].
    Traue J; Kala H; Wenzel U; Wiegeleben A; Pintye-Hódi K; Szabó-Révész P; Miseta M; Selmeczi B; Kedvessy G
    Pharmazie; 1987 Feb; 42(2):86-9. PubMed ID: 3602065
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Preparation and evaluation of itraconazole dihydrochloride for the solubility and dissolution rate enhancement.
    Tao T; Zhao Y; Wu J; Zhou B
    Int J Pharm; 2009 Feb; 367(1-2):109-14. PubMed ID: 18930795
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Simultaneous measurement of liquid-phase and solid-phase transformation kinetics in rotating disc and channel flow cell dissolution devices.
    Lehto P; Aaltonen J; Niemelä P; Rantanen J; Hirvonen J; Tanninen VP; Peltonen L
    Int J Pharm; 2008 Nov; 363(1-2):66-72. PubMed ID: 18675891
    [TBL] [Abstract][Full Text] [Related]  

  • 35. In vitro and in vivo evaluation of a fast-disintegrating lyophilized dry emulsion tablet containing griseofulvin.
    Ahmed IS; Aboul-Einien MH
    Eur J Pharm Sci; 2007 Sep; 32(1):58-68. PubMed ID: 17628451
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Crystal growth formation in melt extrudates.
    Bruce C; Fegely KA; Rajabi-Siahboomi AR; McGinity JW
    Int J Pharm; 2007 Aug; 341(1-2):162-72. PubMed ID: 17524578
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Comparative in vitro studies of allopurinol in commercial preparations].
    Georgarakis M; Iconomout N
    Pharmazie; 1984 Apr; 39(4):248-50. PubMed ID: 6739528
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effect of poloxamer on the dissolution of felodipine and preparation of controlled release matrix tablets containing felodipine.
    Lee KR; Kim EJ; Seo SW; Choi HK
    Arch Pharm Res; 2008 Aug; 31(8):1023-8. PubMed ID: 18787792
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Discrepancy among dissolution rates of commercial tablets as a function of dissolution method. Part 5: In vitro/in vivo correlation for chlorpromazine hydrochloride tablets.
    Ammar HO; Khalil RM; Omar SM
    Pharmazie; 1993 Dec; 48(12):932-5. PubMed ID: 8115438
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The effect of temperature on diametral compression strength of delta-phenylbutazone and barbital (form II) tablets.
    Danjo K; Otsuka A
    Chem Pharm Bull (Tokyo); 1988 Feb; 36(2):763-8. PubMed ID: 3409383
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.